Pavithra Laxsen Anru

Pavithra Laxsen Anru

Auto-generated profile, based on publicly available information

Pavithra Laxsen Anru

Research Unit of Clinical Epidemiology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2020 in European Geriatric Medicine
Verified
Journal Article
Closed access
PDF file
KBKristoffer Kittelmann Brockhattingen
Kristoffer Kittelmann Brockhattingen
PAPavithra Laxsen Anru
Pavithra Laxsen Anru
TMTahir Masud
Tahir Masud
MPMirko Petrovic
Mirko Petrovic
JRJesper Ryg
Jesper Ryg

13 May 2020 in Infectious Diseases
Verified
Journal Article
Closed access
RRRasmus Richelsen
Rasmus Richelsen
JSJesper Smit
Jesper Smit
PAPavithra Laxsen Anru
Pavithra Laxsen Anru
HSHenrik Carl Schønheyder
Henrik Carl Schønheyder
HNHenrik Nielsen
Henrik Nielsen
Background: Data elucidating trends of community-onset extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae infections remain sparse in low prevalence areas. We conducted a population-based study to determine the incidence, temporal trends and co-resistance of community-onset ESBL infections. Methods: We identified all recorded episodes of E. coli and K. pneumoniae bacteraemia and urinary tract infections in adult patients (>15 years) in the North Denmark Region between 2007–2017. Using population-based registries, we obtained information on demographics and place of acquisition, and investigated the standardized incidence rates and temporal trends of community-onset ESBL infections and the associated patterns of co-resistance. Results: A total of 3741 episodes of community-onset ESBL E. coli or K. pneumoniae infections were observed during the study period, with the annual standardized incidence rate increasing from 7.5 to 105 per 100,000 person-years between 2007–2017. The increase was conveyed primarily by a rise in E. coli urinary tract infections shifting from being mainly healthcare-associated to community-acquired. ESBL-producing isolates increased from 0.5 to 4.0% with considerable co-resistance. Conclusion: The proportion of E. coli and K. pneumoniae isolates producing ESBL have increased considerably in the North Denmark Region. The increasing incidence and frequent co-resistance should raise awareness among physicians responsible for empirical antibiotic treatment.

1 June 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
RRRasmus Richelsen
Rasmus Richelsen
JSJesper Smit
Jesper Smit
PAPavithra Laxsen Anru
Pavithra Laxsen Anru
HSHenrik Carl Schønheyder
Henrik Carl Schønheyder
HNHenrik Nielsen
Henrik Nielsen

31 August 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
LJLine Riis Jølving
Line Riis Jølving
PAPavithra Laxsen Anru
Pavithra Laxsen Anru
JNJan Nielsen
Jan Nielsen
SFSonia Friedman
Sonia Friedman
BNBente Mertz Nørgård
Bente Mertz Nørgård

19 August 2021 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
SSSøren Ramsdal Sørensen
Søren Ramsdal Sørensen
JFJeppe Dalskov Frederiksen
Jeppe Dalskov Frederiksen
PAPavithra Laxsen Anru
Pavithra Laxsen Anru
TMTahir Masud
Tahir Masud
MPMirko Petrovic
Mirko Petrovic
JRJesper Ryg
Jesper Ryg
Background Use of drugs with anticholinergic properties (DAP) has a negative impact on older people. Objective Our aim was to examine the association between DAP at hospital admission and mortality in older patients. Patients and Methods We performed a nationwide population-based cohort study including patients aged ≥ 65 years admitted to Danish geriatric medicine departments during 2005–2014. National health registers were used to link with individual-level data. Patients were followed to emigration, death, or study termination (31 December 2015). DAP was defined as medications included in the anticholinergic cognitive burden (ACB) scale, which assigns each DAP a score between 1 and 3. The individual ACB score was calculated and the number of DAP counted. We used Cox proportional-hazard regressions to estimate the crude and adjusted hazard ratios adjusting for age, activities of daily living, marital status, index admission period, BMI, and prior hospitalizations (model 1), and additionally Charlson Comorbidity Index (model 2). Results We included 74,589 patients aged (median [IQR]) 83 (77–88) years. Use of one or more DAP (62.5%) was associated with increased mortality compared with those with no use (p < 0.001). In the fully adjusted model 2, compared with no use, higher mortality risks (HR [95% CI]) were seen with ACB score of 2 and number of DAP ≥ 5 for 30-day (1.46 [1.32–1.61] and 1.46 [1.09–1.95]), 1-year (1.34 [1.28–1.41] and 1.48 [1.29–1.70]), and overall mortality (1.27 [1.23–1.31] and 1.44 [1.31–1.59]), respectively. Conclusions Use of DAP at hospital admission is associated with short- and long-term mortality in geriatric patients. Deprescribing studies are warranted to study whether the impact on mortality can be attenuated.